The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex

International Journal of Neuropsychopharmacology

Volumn 15, Issue 7, 2012, Pages 907-917

  Kim, Min Kyung ^a,b   Kim, Se Hyun ^a,b   Yu, Hyun Sook ^a,b   Park, Hong Geun ^a,b   Kang, Ung Gu ^a   Ahn, Yong Min ^a   Kim, Yong Sik ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Acetyl CoA carboxylase; AMP activated protein kinase; antipsychotics; carnitine palmitoyltransferase 1; metabolic signal pathway

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CARNITINE PALMITOYLTRANSFERASE I; CLOZAPINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FRONTAL CORTEX; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CARNITINE O-PALMITOYLTRANSFERASE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FRONTAL LOBE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84864358247     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000976     Document Type: Article

References (60)

1. Allison DB, Mentore JL, Heo M, Chandler LP, et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156, 1686-1696. (Pubitemid 29517559)
2. Artigas F (2010). The prefrontal cortex : a target for antipsychotic drugs. Acta Psychiatrica Scandinavica 121, 11-21.
3. Bateup HS, Svenningsson P, Kuroiwa M, Gong S, et al. (2008). Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nature Neuroscience 11, 932-939.
4. Boone AN, Rodrigues B, Brownsey RW (1999). Multiple-site phosphorylation of the 280 kDa isoform of acetyl-CoA carboxylase in rat cardiac myocytes: evidence that cAMP-dependent protein kinase mediates effects of beta-adrenergic stimulation. Biochemical Journal 341, 347-354. (Pubitemid 29373659)
5. Bruce CR, Hoy AJ, Turner N, Watt MJ, et al. (2009). Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes 58, 550-558.
6. Carling D (2004). The AMP-activated protein kinase cascade-a unifying system for energy control. Trends in Biochemical Sciences 29, 18-24. (Pubitemid 38068476)
7. Carling D, Zammit VA, Hardie DG (1987). A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Letters 223, 217-222.
8. Casey DE (2004). Dyslipidemia and atypical antipsychotic drugs. Journal of Clinical Psychiatry 65, 27-35.
9. Chattopadhyay A, Paila YD (2007). Lipid-protein interactions, regulation and dysfunction of brain cholesterol. Biochemical and Biophysical Research Communications 354, 627-633. (Pubitemid 46186247)
10. Coccurello R, Moles A (2010). Potential mechanisms of atypical antipsychotic-induced metabolic derangement : clues for understanding obesity and novel drug design. Pharmacology and Therapeutics 127, 210-251.
11. da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, et al. (2003). Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochemical Journal 371, 761-774. (Pubitemid 36578875)
12. Dasgupta B, Milbrandt J (2009). AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Developmental Cell 16, 256-270.
13. Dwyer DS, Donohoe D, Lu XH, Aamodt EJ (2005). Mechanistic connections between glucose/lipid disturbances and weight gain induced by antipsychotic drugs. International Review of Neurobiology 65, 211-247. (Pubitemid 43588584)
14. Folmes CD, Lopaschuk GD (2007). Role of malonyl-CoA in heart disease and the hypothalamic control of obesity. Cardiovascular Research 73, 278-287. (Pubitemid 44937698)
15. Gaidhu MP, Fediuc S, Ceddia RB (2006). 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside-induced AMPactivated protein kinase phosphorylation inhibits basal and insulin-stimulated glucose uptake, lipid synthesis, and fatty acid oxidation in isolated rat adipocytes. Journal of Biological Chemistry 281, 25956-25964. (Pubitemid 44401801)
16. Hardie DG, Carling D (1997). The AMP-activated protein kinase-fuel gauge of the mammalian cell? European Journal of Biochemistry 246, 259-273. (Pubitemid 27232500)
17. Hardie DG, Carling D, Sim ATR (1989). The AMPactivated protein-kinase-a Multisubstrate Regulator of Lipid-Metabolism. Trends in Biochemical Sciences 14, 20-23. (Pubitemid 19031701)
18. Hardie DG, Pan DA (2002). Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochemical Society Transactions 30, 1064-1070. (Pubitemid 36002407)
19. Hawley SA, Boudeau J, Reid JL, Mustard KJ, et al. (2003). Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. Journal of Biology 2, 28.
20. Hawley SA, Davison M, Woods A, Davies SP, et al. (1996). Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. Journal of Biological Chemistry 271, 27879-27887. (Pubitemid 26367365)
21. Hazlett EA, Buchsbaum MS, Jeu LA, Nenadic I, et al. (2000). Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task. Schizophrenia Research 43, 33-46. (Pubitemid 30316315)
22. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, et al. (2004). Clozapine and hypertension : a chart review of 82 patients. Journal of Clinical Psychiatry 65, 686-689.
23. Horrobin DF, Manku MS, Hillman H, Iain A, et al. (1991). Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry 30, 795-805.
24. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
25. Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27, 1081-1090. (Pubitemid 37464954)
26. Kim JH, Lee JO, Lee SK, Jung JH, et al. (2010a). Clozapine activates AMP-activated protein kinase (AMPK) in C2C12 myotube cells and stimulates glucose uptake. Life Sciences 87, 42-48.
27. Kim SF, Huang AS, Snowman AM, Teuscher C, et al. (2007). From the Cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proceedings of the National Academy of Sciences USA 104, 3456-3459. (Pubitemid 46364180)
28. Kim SH, Park HG, Kim HS, Ahn YM, et al. (2010b). Effects of neonatal MK-801 treatment on p70S6 KS6/eIF4B signal pathways and protein translation in the frontal cortex of the developing rat brain. International Journal of Neuropsychopharmacology 13, 1233-1246.
29. Kim SH, Yu HS, Park HG, Jeon WJ, et al. (2008). Dose-dependent effect of intracerebroventricular injection of ouabain on the phosphorylation of the MEK1/2-ERK1/2-p90RSK pathway in the rat brain related to locomotor activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 1637-1642.
30. Kola B, Boscaro M, Rutter GA, Grossman AB, et al. (2006). Expanding role of AMPK in endocrinology. Trends in Endocrinology and Metabolism 17, 205-215. (Pubitemid 43974977)
31. Kuramoto N, Wilkins ME, Fairfax BP, Revilla-Sanchez R, et al. (2007). Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron 53, 233-247. (Pubitemid 46074400)
32. Lewis SW, Barnes TR, Davies L, Murray RM, et al. (2006). Randomized controlled trial of effect of prescription of clozapine vs. other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715-723. (Pubitemid 44412859)
33. López M, Lage R, Saha AK, Pérez-Tilve D, et al. (2008). Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metabolism 7, 389-399. (Pubitemid 351618114)
34. Ma J, Ye N, Cohen BM (2006). Typical and atypical antipsychotic drugs target dopamine and cyclic AMP-regulated phosphoprotein, 32 kDa and neurotensin-containing neurons, but not GABAergic interneurons in the shell of nucleus accumbens of ventral striatum. Neuroscience 141, 1469-1480. (Pubitemid 44128690)
35. MacDonald ML, Eaton ME, Dudman JT, Konradi C (2005). Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biological Psychiatry 57, 1041-1051. (Pubitemid 40603087)
36. Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, et al. (2009). Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 9, 17.
37. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, et al. (2006). CATIE Investigators.Effectiveness of clozapine vs. olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600-610. (Pubitemid 44464569)
38. Meyer JM, Koro CE (2004). The effects of antipsychotic therapy on serum lipids : a comprehensive review. Schizophrenia Research 70, 1-17. (Pubitemid 38916622)
39. Middleton FA, Mirnics K, Pierri JN, Lewis DA, et al. (2002). Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. Journal of Neuroscience 22, 2718-2729. (Pubitemid 37465821)
40. Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J (2010). Clozapine for treatment-resistant schizophrenia : National Institute of Clinical Excellence (NICE) guidance in the real world. Clinical Schizophrenia and Related Psychoses 4, 49-55.
41. Narayan S, Head SR, Gilmartin TJ, Dean B, et al. (2009). Evidence for disruption of sphingolipid metabolism in schizophrenia. Journal of Neuroscience Research 87, 278-288.
42. Paxinos G, Watson C (1998). The Rat Brain in Stereotactic Coordinates, 4th edn. Sydney: Academic Press.
43. Pearce JM, Komoroski RA, Mrak RE (2009). Phospholipid composition of postmortem schizophrenic brain by 31P NMR spectroscopy. Magnetic Resonance in Medicine 61, 28-34.
44. Potter WB, O'Riordan KJ, Barnett D, Osting SM, et al. (2010). Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One 5, e8996.
45. Pozzi L, Ha?kansson K, Usiello A, Borgkvist A, et al. (2003). Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. Journal of Neurochemistry 86, 451-459. (Pubitemid 36842444)
46. Ramamurthy S, Ronnett GV (2006). Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. Journal of Physiology 574, 85-93. (Pubitemid 43905799)
47. Roh MS, Seo MS, Kim Y, Kim SH, et al. (2007). Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Experimental and Molelcular Medicine 39, 353-360. (Pubitemid 47037626)
48. Ronnett GV, Kleman AM, Kim EK, Landree LE, et al. (2006). Fatty acid metabolism, the central nervous system, and feeding. Obesity (Silver Spring) 14, 201S-207S.
49. Ruderman NB, Saha AK, Kraegen EW (2003). Minireview: malonyl CoA, AMP-activatedprotein kinase, and adiposity. Endocrinology 144, 5166-5171.
50. Rushlow WJ, Seah C, Sutton LP, Bjelica A, et al. (2009). Antipsychotics affect multiple calcium calmodulin dependent proteins. Neuroscience 161, 877-886.
51. Sapkota GP, Kieloch A, Lizcano JM, Lain S, et al. (2001). Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90 (RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys (433), is essential for LKB1 to suppress cell vrowth. Journal of Biological Chemistry 276, 19469-19482.
52. Shin ES, Cho SY, Lee EH, Lee SJ, et al. (2006a). Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. European Journal of Nutrition 45, 159-164.
53. 2+/calmodulin in PTEN-negative U-87MG human glioblastoma cells. Cellular Signalling 18, 1876-1886. (Pubitemid 44485978)
54. Sierra AY, Gratacós E, Carrasco P, Clotet J, et al. (2008). CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. Journal of Biological Chemistry 283, 6878-6885.
55. 2+/calmodulindependent protein kinases. Cellular and Molecular Life Sciences 65, 2637-2657.
56. Takami G, Ota M, Nakashima A, Kaneko YS, et al. (2010). Effects of atypical antipsychotics and haloperidol on PC12 cells : only aripiprazole phosphorylates AMP-activated protein kinase. Journal of Neural Transmission 117, 1139-1153.
57. Washington L, Cook GA, Mansbach 2nd CM (2003). Inhibition of carnitine palmitoyltransferase in the rat small intestine reduces export of triacylglycerolinto the lymph. Journal of Lipid Research 44, 1395-1403. (Pubitemid 37279622)
58. 2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metabolism 2, 21-33. (Pubitemid 43239822)
59. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, et al. (2002). Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 8, 1288-1295. (Pubitemid 35373562)
60. Zhang BB, Zhou G, Li C (2009). AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metabolism 9, 407-416.